MedTrace Logo

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

NCT04337099 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-05-05

No results posted yet for this study

Summary

A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.

Conditions

Interventions

DRUG

MBM-02 (Tempol)

Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.

Sponsors & Collaborators

  • Matrix Biomed, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337099 on ClinicalTrials.gov